TABLE 2.

Prior exposure to medications for VMS

Medication	Placebo (n = 43)	Fezolinetant
		15 mg BID (n = 45)	30 mg BID (n = 43)	60 mg BID (n = 45)	90 mg BID (n = 44)	30 mg QD (n = 43)	60 mg QD (n = 45)	120 mg QD (n = 44)
Sex hormones and modulators of the genital system, n (%)a	4 (9.3)	1 (2.2)	1 (2.3)	0	3 (6.8)	2 (4.7)	3 (6.7)	1 (2.3)
Estrogen and/or progestogen therapy, n (%)
Estradiol	2 (4.7)	0	1 (2.3)	0	0	2 (4.7)	1 (2.2)	0
Estradiol benzoate	0	0	0	0	1 (2.3)	0	0	0
Conjugated estrogens	2 (4.7)	0	0	0	1 (2.3)	0	0	0
Progesterone	0	0	0	0	0	0	1 (2.2)	0
Estrogen/progestogen combinations	0	0	0	0	1 (2.3)	0	1 (2.2)	0
Otherb	1 (2.3)	1 (2.2)	0	0	0	0	1 (2.2)	1 (2.3)
SSRIs (paroxetine or paroxetine mesylate), n (%)	1 (2.3)	0	0	0	0	0	0	1 (2.3)

SSRI, selective serotonin reuptake inhibitor; VMS, vasomotor symptoms.

^aTotal N for the category in each treatment group may be less than the sum of the n's for the individual medications as participants may have taken more than one medication.

^bIncludes herbal treatments with estrogen-like activity (cimicifuga racemosa extract) and chorionic gonadotrophin.